

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS & FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA  
UNSTARRED QUESTION NO. 2139  
TO BE ANSWERED ON THE 29<sup>th</sup> July, 2022

**Research and Development of Drugs**

**2139. SHRI MANOJ KOTAK:  
SHRIMATI RAKSHA NIKHIL KHADSE:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) whether the Government has launched any programme or policy for Research and Development (R&D) of drugs through various schemes;
- (b) if so, the details thereof along with the new drugs developed, R&D expenditure of Indian pharmaceutical companies/Public Sector Undertakings (PSUs) during the last three years, year-wise; and
- (c) whether National Institutes of Pharmaceutical Education & Research (NIPERs) has conducted research in various pharma specializations and if so, the details thereof?

**ANSWER**

**MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS  
(SHRI BHAGWANTH KHUBA)**

---

(a) and (b): Research and Development (R&D) in pharma sector is done by number of institutions and organizations under various scientific Ministries/ Departments as well as by pharmaceutical companies.

Department of Pharmaceuticals (DoP) has set up seven National Institutes of Pharmaceutical Education & Research (NIPERs) as institutes of national importance to nurture and promote quality and excellence in pharmaceutical education and research in India, which besides imparting postgraduate and doctorate education, conduct high end research in various pharma specializations. DoP has also set up an Inter- Departmental Committee (IDC) to periodically review and coordinate research work undertaken by various organizations under different Ministries/ Departments so as to ensure optimum utilization of funds and avoid overlapping and duplication of efforts and resources.

Department of Biotechnology (DBT), along with its Public Sector Undertaking (PSU) Biotechnology Industry Research Assistance Council (BIRAC) has facilitated implementation of Research and Development (R&D) projects for drug discovery in the areas of Tuberculosis (TB), Anti-Microbial Resistance (AMR), Diabetes, Cancer, Wound management, Autoimmune disorders and Rare Diseases, through the regular schemes of DBT and BIRAC.

The year-wise details of the fund disbursements by BIRAC to grantees during the last 3 years to support R&D projects for drug development are as follows:

	<b>2019-20</b>	<b>2020-21</b>	<b>2021-22</b>	<b>Total</b>
<b>Amount Released ( Rs in Lakhs)</b>	826.72	498.13	419.13	<b>1743.98</b>

Council of Scientific and Industrial Research (CSIR) through its various constituent laboratories is engaged in the research and development of the process technologies for Active Pharmaceutical Ingredients (API) and intermediates. CSIR has approved various significant projects, including projects on basic research, in the area of drug discovery and development worth about Rs. 284.88 cr. for the period 2020-21 to 2025-26.

The details of R&D expenditure incurred by pharmaceutical companies are not readily available with the department. As regard pharma PSUs under DoP, it is informed that all of them have been identified for closure or strategic sale. The details of R&D expenditure of three functional PSUs (KAPL, HAL & BCPL) under DoP are as under: -

	(Rs. in Lakh)		
<b>PSU</b>	<b>2019-20</b>	<b>2020-21</b>	<b>2021-22</b>
Karnataka Antibiotics & Pharmaceuticals Ltd. (KAPL)	125.48	35.88	41.24
Hindustan Antibiotics Ltd. (HAL)	127.86	97.00	92.66
Bengal Chemicals & Pharmaceuticals Ltd. (BCPL)	11.00	15.00	16.00

(c): NIPERs are actively & dedicatedly engaged in cutting-edge advanced translational pharmaceutical research in various pharma specializations. The areas of research include cancer, diabetes, Neurodegenerative Disease, TB, Phytopharmaceuticals, New process development of Generic API molecules, Drug Delivery System, development of Nano-drug Formulations etc.

\*\*\*\*\*